TenQ · fact sheet · filings current to · price as of
Vertex Pharmaceuticals (VRTX)
Strong business, priced for a lot of it - 22 of 36 checks passed.
Latest close : $546.12, -2.1% on the day; -2.1% from the 52-week high. Refreshed every trading night.
Full analysis: report · all charts. Financial statements are computed from SEC EDGAR XBRL filings, current to . The share price and everything built on it (market cap, multiples, yields, the Value and Trend checks) are refreshed every trading night; this page shows the close of . Not investment advice.
Key figures
| Share price (delayed close) | $546.12 |
| Market cap | $138.4B |
| 52-week range | $376.62 - $557.96 |
| P/E | 32.0x |
| P/E, own 8-year median | 24.4x |
| P/S | 11.0x |
| Free cash flow yield | 2.7% |
| Dividend yield | - |
| Revenue (TTM) | $12.6B |
| Net income (TTM) | $4.4B |
| Free cash flow (TTM) | $3.8B |
| Gross margin | 86.0% |
| Operating margin | 38.0% |
| Return on equity | 21.8% |
| Revenue growth (1y) | +10.2% |
| Revenue CAGR (3y) | +10.4% |
| Debt / equity | - |
| Cash & short-term investments | $7.9B |
| Shares outstanding | 253.5m (cover page of the latest filing, 2026-07-31) |
The score: 22 of 36 checks passed
Six chapters, six pass/fail checks each. Five are computed from the filings; Trend is price behaviour, and says so.
Is VRTX stock cheap or expensive right now?
Value · 0 of 6 checks passed. Expensive against its own history and its sector - you're paying up for what you get. chapter →
Is Vertex Pharmaceuticals still growing?
Growth · 2 of 6 checks passed. Growth is weak or inconsistent - the trend, not the story, is the problem. chapter →
Does Vertex Pharmaceuticals make real money?
Quality · 6 of 6 checks passed. Rare profitability: margins and returns on capital are well above its peers. chapter →
Can Vertex Pharmaceuticals survive a bad year?
Health · 5 of 6 checks passed. A fortress balance sheet - VRTX can survive a very bad year. chapter →
What does Vertex Pharmaceuticals hand back to shareholders?
Shareholder returns · 3 of 6 checks passed. Cash comes back to owners, with a caveat or two in the checks below. chapter →
Which way is VRTX trending?
Trend analysis · 6 of 6 checks passed. The market agrees: the stock is in a healthy uptrend on every horizon. chapter →
Are insiders buying or selling VRTX?
Open-market buys: $0.00 · sells: $38M, across the recent Form 4 filings. detail →
Other pharma and chemicals we cover: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · Procter & Gamble (PG) · Amgen (AMGN) · every company →
Method: figures computed deterministically from SEC EDGAR XBRL (companyfacts, frames, financial-statement-and-notes datasets, Form 4); prices delayed end-of-day. Scores count transparent pass/fail checks. Missing data is shown as missing, never estimated. Last changed . © TenQ - cite with a link to this page.